Formulation and Characterization of Nano Lipid Carrier Dry Powder Inhaler Containing Ciprofloxacin Hydrochloride and N-Acetyl Cysteine
Keywords:
Ciprofloxacin Hydrochloride, N-Acetyl Cysteine, Nano lipid Carriers, Dry powder inhaler, cystic fibrosisAbstract
Nanolipid carriers (NLC) are developed as an alternative to solid lipid nanocarriers in order to increase the payload and to prevent drug expulsion. In this study, NLCs loaded with ciprofloxacin hydrochloride (CIP) and N-Acetyl cysteine (NAC) were prepared and evaluated for its delivery to the lung for treatment of the symptoms of cystic fibrosis and chronic obstructive pulmonary disorder.NLCs prepared by emulsification and sonication technique using cetyl palmitate (the solid lipid, 2%) and oleic acid (as the liquid lipid, 2%) and Tween80 (surfactant, 0.25%) showed smaller particle sizes (of199.1 ±1.859 nm) and relatively high encapsulation efficiencies (72.143±1.8 %.) and optimum zeta potential (-38.27 ± 0.384 mV).A novel DPI formulations loaded with the NLC containing CIP(CIP-DPI), NAC (NAC-DPI) and CIP/NAC combination (CIP-NAC-DPI) wereprepared by freeze drying method using Lactose (8%w/v) as a cryoprotectant. The DPI prepared showed good flow properties, prolonged drug release and improved stability.In-vitro drug release profile of CIP HCl in case of CIP-NLC showed 55 % release in 15 hours while it was 60% in case of CIP-NLCDPI formulation. Similar is the case with NAC formulations. Following intratracheal administration in rat model, the percentage of CIP extracted from lungs was 70.2% in case on CIP-NAC-DPI against 49.8% for CIP-DPI and 42.1% for plain CIP. This amount is about 1.6 times increase in CIP in lungs by co-administration with NAC. However, no appreciable change in the residence time of CIP in lungs after intratracheal administration of CIP-DPI and combined DPI (CIP-NAC-DPI) was noted.
References
. Courtney JM, Ennis M, Elborn JS.
Cytokines and inflammatory
mediators in cystic fibrosis. J Cyst
Fibros. 2004;3(4): 223-31.
. Driscoll JA, Brody SL, Kollef MH.
The epidemiology, pathogenesis
and treatment of Pseudomonas
aeruginosa infections. Drugs, 2007.
(3): 351-68.
. Pauwels RA. et al., Effect of inhaled
formoterol and budesonide on
exacerbations of asthma.
Formoterol and Corticosteroids
Establishing Therapy (FACET)
International Study Group. N Engl J
Med, 1997. 337(20): 1405-11.
. Edsbacker S, Johansson CJ.
Airway selectivity: an update of
pharmacokinetic factors affecting
local and systemic disposition of
inhaled steroids. Basic Clin
Pharmacol Toxicol, 2006. 98(6):
-36.
. Abu-Dahab R, Schafer UF, Lehr
CM. Lectin-functionalized liposomes
for pulmonary drug delivery: effect
of nebulization on stability and
bioadhesion. Eur J Pharm Sci,
14(1): 37-46.
. Bailey MM, Berkland CJ.
Nanoparticle formulations in
pulmonary drug delivery. Med Res
Rev, 2009. 29(1): p. 196-212.
. Chono S. et al., Efficient drug
delivery to lung epithelial lining fluid
by aerosolization of ciprofloxacin
incorporated into PEGylated
liposomes for treatment of
respiratory infections. Drug Dev Ind
Pharm, 2011. 37(4): 367-72.
. Pourshahab PS. et al., Preparation
and characterization of spray dried
inhalable powders containing
chitosan nanoparticles for
pulmonary delivery of isoniazid. J
Microencapsul, 2011. 28(7): 605-
. Jores K. et al., Solid lipid
nanoparticles (SLN) and oil-loaded
SLN studied by spectrofluorometry
and Raman spectroscopy. Pharm
Res, 2005. 22(11): 1887-97.
. Wong, JP. et al., Liposome delivery
of ciprofloxacin against intracellular
Francisella tularensis infection. J
Control Release, 2003. 92(3): 265-
. Alovero FL, Olivera ME, Manzo RH.
In vitro pharmacodynamic
properties of a fluoroquinolone
pharmaceutical derivative:
hydrochloride of ciprofloxacinaluminium complex. Int J Antimicrob
Agents, 2003. 21(5): 446-51.
. Li, FQ. et al., Ciprofloxacin-loaded
bovine serum albumin
microspheres: preparation and
drug-release in vitro. J
Microencapsul, 2001. 18(6): 825-9.
. Finlay WH, Wong JP. Regional
lung deposition of nebulized
liposome encapsulated
ciprofloxacin. Int. J. Pharm,
(167): 121-127.
. Hodson ME. et al., Dornase alfa in
the treatment of cystic fibrosis in
Europe: a report from the
Epidemiologic Registry of Cystic
Fibrosis. Pediatr Pulmonol, 2003.
(5): 427-32.
. Deterding R. et al., Safety and
tolerability of denufosol tetrasodium
inhalation solution, a novel P2Y2
receptor agonist: results of a phase
/phase 2 multicenter study in mild
to moderate cystic fibrosis. Pediatr
Pulmonol, 2005. 39(4): 339-48.
. Jones AM, Helm JM. Emerging
treatments in cystic fibrosis. Drugs,
69(14): 1903-10.
. Donaldson SH. et al., Mucus
clearance and lung function in
cystic fibrosis with hypertonic
saline. N Engl J Med, 2006. 354(3):
-50.
. Serisier DJ. et al., Inhaled heparin
in cystic fibrosis. Eur Respir J,
27(2): 354-8.
. 1Suk JS. et al., Rapid transport of
muco-inert nanoparticles in cystic
fibrosis sputum treated with Nacetyl cysteine. Nanomedicine
(Lond), 2011. 6(2): 365-75.
. Matsuyama T. et al., Improved
nasal absorption of salmon
calcitonin by powdery formulation
with N-acetyl-L-cysteine as a
mucolytic agent. J Control Release,
115(2): 183-8.
. Daviskas E. et al., Inhalation of drypowder mannitol increases
mucociliary clearance. Eur Respir J,
10(11): 2449-54.
. Suk, JS. et al., N-acetylcysteine
enhances cystic fibrosis sputum
penetration and airway gene
transfer by highly compacted DNA
nanoparticles. Mol Ther, 2011.
(11): 1981-9.
. Parry MF, Neu HC. Effect of Nacetylcysteine on antibiotic activity
and bacterial growth in vitro. J Clin
Microbiol, 1977. 5(1): 58-61.
. Lawson D, Saggers BA. N.A.C. And
Antibiotics in Cystic Fibrosis. Br
Med J, 1965. 1(5430): 317.
. Heaf DP, Webb GJ, Matthew DJ. In
vitro assessment of combined
antibiotic and mucolytic treatment
for Pseudomonas aeruginosa
infection in cystic fibrosis. Arch Dis
Child, 1983. 58(10): 824-6.
. El-Feky MA. et al., Effect of
ciprofloxacin and N-acetylcysteine
on bacterial adherence and biofilm
formation on ureteral stent surfaces.
Pol J Microbiol, 2009. 58(3): 261-7.
. Ozdil B. et al., Potential benefits of
combined N-acetylcysteine and
ciprofloxacin therapy in partial
biliary obstruction. J Clin
Pharmacol, 2010. 50(12): 1414-9.
. Yang Y. et al., Mannitol-guided
delivery of Ciprofloxacin in artificial
cystic fibrosis mucus model.
Biotechnol Bioeng, 2011. 108(6):
-9.
. Chattopadhyay N. et al., Solid lipid
nanoparticles enhance the delivery
of the HIV protease inhibitor,
atazanavir, by a human brain
endothelial cell line. Pharm Res,
25(10): 2262-71.
. Joshi MR, Misra A. Liposomal
budesonide for dry powder inhaler:
preparation and stabilization. AAPS
PharmSciTech, 2001. 2(4): 25.
. Liu D. et al., Nanostructured lipid
carriers as novel carrier for
parenteral delivery of docetaxel.
Colloids Surf B Biointerfaces, 2011.
(2): 262-9.
. Jurima-Romet M, Shek PN. Lung
Uptake of Liposome-entrapped
Glutathione After Intratracheal
Administration. Journal of
Pharmacy and Pharmacology,
43(1): 6-10.
. Joshi M, Misra A. Disposition
kinetics of ketotifen from liposomal
dry powder for inhalation in rat lung.
Clin Exp Pharmacol Physiol, 2003.
(3): 153-6.
. Webb MS. et al., Antibacterial
efficacy against an in vivo
Salmonella typhimurium infection
model and pharmacokinetics of a
liposomal ciprofloxacin formulation.
Antimicrob Agents Chemother,
42(1): 45-52.
. App EM.et al., Dose-finding and 24-
h monitoring for efficacy and safety
of aerosolized Nacystelyn in cystic
fibrosis. Eur Respir J, 2002. 19(2):
-302.
